Sperm Selection by Rheotaxis and Thermotaxis in In-Situ Handmade Microfluidics of Fluidic Walls in the Same ICSI Plate
Launched by CREA MEDICINA DE LA REPRODUCCIÓN SL · Feb 5, 2024
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to select sperm for a procedure called Intracytoplasmic Sperm Injection (ICSI), which is used to help people achieve pregnancy. The researchers are comparing two methods: the traditional technique called Density-Gradient Centrifugation (DGC) and a new handmade approach that uses special fluid walls to guide sperm movement based on their natural swimming behavior. The goal is to see which method better selects the best sperm to improve the chances of a successful ICSI procedure.
To participate in this trial, you need to be a female under 40 years old undergoing ICSI, have at least 6 mature eggs retrieved, and a male partner under 50 with at least 1 million moving sperm. This trial is currently recruiting participants, and it's important to note that it excludes those using surgically retrieved or frozen eggs and sperm. If you join, you can expect to contribute to important research that may improve fertility treatments in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing ICSI
- • Female age under 40 years old
- • Number of mature oocytes (MII) upon oocyte retrieval ≥ 6
- • Male age under 50 years old
- • Total number of progressive sperm ≥ 1 million
- Exclusion Criteria:
- • Patients with surgically retrieved sperm for ICSI
- • Cases using cryopreserved oocytes
- • Cases using cryopreserved sperm
About Crea Medicina De La Reproducción Sl
Crea Medicina de la Reproducción SL is a leading clinical trial sponsor specializing in reproductive medicine. With a commitment to advancing the field through innovative research and development, Crea collaborates with healthcare professionals and institutions to conduct rigorous clinical trials aimed at improving fertility treatments and outcomes. The organization is dedicated to enhancing patient care through evidence-based practices, leveraging cutting-edge technologies, and fostering a multidisciplinary approach to reproductive health. Crea's expertise and dedication position it as a pivotal player in the advancement of reproductive medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Valencia, , Spain
Patients applied
Trial Officials
Miguel Ruiz-Jorro MD, MSc, PhD
Principal Investigator
CREA. Medicina de la Reproducción S.L.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported